These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38327983)

  • 1. Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS).
    Bao Y; Chen J; Duan L; Wang F; Lai H; Mo Z; Zhu W
    Front Pharmacol; 2024; 15():1288362. PubMed ID: 38327983
    [No Abstract]   [Full Text] [Related]  

  • 2. Adverse Event Profile Differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: A Real-world, Pharmacovigilance Study.
    Liu F; Yin G; Xue S; Rehman FU; Liao D; Pan Y
    J Cancer; 2023; 14(17):3275-3284. PubMed ID: 37928419
    [No Abstract]   [Full Text] [Related]  

  • 3. High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database.
    Ma P; Tian H; Shi Q; Liu R; Zhang Y; Qi X; Chen Y
    Expert Opin Drug Saf; 2023; 22(8):685-696. PubMed ID: 37068935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS).
    Zhou J; Zhang J; Wang Q; Peng M; Qian Y; Wu F; Rao Q; DanZhen L; Yang Y; Wang S; Liu M
    Ther Adv Drug Saf; 2024; 15():20420986241284105. PubMed ID: 39381060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS.
    Chai S; Zhan JL; Zhao LM; Liu XD
    Ther Adv Drug Saf; 2022; 13():20420986221143266. PubMed ID: 36545565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review.
    Perez EA; Dang C; Lee C; Singh J; Wang K; Layton JB; Gilsenan A; Hackshaw MD; Cortes J
    Breast Cancer Res Treat; 2022 Jul; 194(1):1-11. PubMed ID: 35587323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration's adverse event reporting system databases.
    Liang Q; Liao X; Wu H; Huang Y; Liang T; Li H
    Front Pharmacol; 2024; 15():1431562. PubMed ID: 39144633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System.
    Cecco S; Puligheddu S; Fusaroli M; Gerratana L; Yan M; Zamagni C; De Ponti F; Raschi E
    Target Oncol; 2024 May; 19(3):435-445. PubMed ID: 38696126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
    BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer.
    Waliany S; Caswell-Jin J; Riaz F; Myall N; Zhu H; Witteles RM; Neal JW
    JACC CardioOncol; 2023 Feb; 5(1):85-98. PubMed ID: 36875913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS).
    Tang L; Sun C; Liu W; Wu H; Ding C
    Front Pharmacol; 2024; 15():1362484. PubMed ID: 38384285
    [No Abstract]   [Full Text] [Related]  

  • 12. Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system.
    Li L; Xu Q; Liu Y; Pang L; Cui Z; Lu Y
    Front Pharmacol; 2024; 15():1403988. PubMed ID: 39114358
    [No Abstract]   [Full Text] [Related]  

  • 13. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
    Yin Y; Shu Y; Zhu J; Li F; Li J
    Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.
    Jiang T; Su H; Xu J; Li C; Zhang N; Li Y; Wu Y; Ni R; Ming Y; Li Z; Li L; Liu Y
    Ther Adv Drug Saf; 2024; 15():20420986231224227. PubMed ID: 38293566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.
    Borges VF; Ferrario C; Aucoin N; Falkson C; Khan Q; Krop I; Welch S; Conlin A; Chaves J; Bedard PL; Chamberlain M; Gray T; Vo A; Hamilton E
    JAMA Oncol; 2018 Sep; 4(9):1214-1220. PubMed ID: 29955792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile and signal detection of phosphodiesterase type 5 inhibitors for erectile dysfunction: a Food and Drug Administration Adverse Event Reporting System analysis.
    Shin YE; Rojanasarot S; Hincapie AL; Guo JJ
    Sex Med; 2023 Oct; 11(5):qfad059. PubMed ID: 38034088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
    Kong W; Mao W; Zhang L; Wu Y
    Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database.
    Long P; Li S; Pan L; Wang Y; Chen W; Wang X
    Front Pharmacol; 2024; 15():1378010. PubMed ID: 38766629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study.
    Li Y; Li H; Xiang Z
    Heliyon; 2024 Mar; 10(6):e27599. PubMed ID: 38510044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.
    Strickler JH; Cercek A; Siena S; André T; Ng K; Van Cutsem E; Wu C; Paulson AS; Hubbard JM; Coveler AL; Fountzilas C; Kardosh A; Kasi PM; Lenz HJ; Ciombor KK; Elez E; Bajor DL; Cremolini C; Sanchez F; Stecher M; Feng W; Bekaii-Saab TS;
    Lancet Oncol; 2023 May; 24(5):496-508. PubMed ID: 37142372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.